Immunohistochemical staining of Slit2 in primary and metastatic prostatic adenocarcinoma

Translational Oncology

Volumn 4, Issue 5, 2011, Pages 314-320

  Bartholow, Tanner L ^a   Becich, Michael J ^a   Chandran, Uma R ^a   Parwani, Anil V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SLIT2 PROTEIN;

ADULT; AGED; ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 80053372828     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11151     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, and Feuer EJ (2002). Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94, 981-990.
3. Joniau S and Van Poppel H (2008). Localized prostate cancer: can we better define who is at risk of unfavourable outcome? BJU Int 101(suppl 2), 5-10.
4. Moul JW (2008). Are we overtreating prostate cancer? J Urol 180, 2299-2300.
5. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, and Gilbertson J (2005). Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5, 45.
6. Georgas K, Burridge L, Smith K, Holmes GP, Chenevix-Trench G, Ioannou PA, and Little MH (1999). Assignment of the human slit homologue SLIT2 to human chromosome band 4p15.2. Cytogenet Cell Genet 86, 246-247.
7. Morlot C, Thielens NM, Ravelli RB, Hemrika W, Romijn RA, Gros P, Cusack S, and McCarthy AA (2007). Structural insights into the Slit-Robo complex. Proc Natl Acad Sci USA 104, 14923-14928.
8. Wong K, Park HT, Wu JY, and Rao Y (2002). Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Curr Opin Genet Dev 12, 583-591.
9. Dickson BJ and Gilestro GF (2006). Regulation of commissural axon pathfinding by slit and its Robo receptors. Annu Rev Cell Dev Biol 22, 651-675.
10. Wu JY, Feng L, Park HT, Havlioglu N, Wen L, Tang H, Bacon KB, Jiang Z, Zhang X, and Rao Y (2001). The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature 410, 948-952.
11. Liu D, Hou J, Hu X, Wang X, Xiao Y, Mou Y, and De Leon H (2006). Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation. Circ Res 98, 480-489.
12. Schmid BC, Rezniczek GA, Fabjani G, Yoneda T, Leodolter S, and Zeillinger R (2007). The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat 106, 333-342.
13. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, and Latif F (2002). SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 62, 5874-5880.
14. Dunwell TL, Dickinson RE, Stankovic T, Dallol A, Weston V, Austen B, Catchpoole D, Maher ER, and Latif F (2009). Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics 4, 265-269.
15. Dallol A, Krex D, Hesson L, Eng C, Maher ER, and Latif F (2003). Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene 22, 4611-4616.
16. Astuti D, Da Silva NF, Dallol A, Gentle D, Martinsson T, Kogner P, Grundy R, Kishida T, Yao M, Latif F, et al. (2004). SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma. Br J Cancer 90, 515-521.
17. Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, Durst M, Mansukhani M, Pothuri B, and Murty VV (2006). Promoter hypermethylationmediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer 5, 16.
18. Jin J, You H, Yu B, Deng Y, Tang N, Yao G, Shu H, Yang S, and Qin W (2009). Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun 379, 86-91.
19. Zheng D, Liu BB, Liu YK, Kang XN, Sun L, Guo K, Sun RX, Chen J, and Zhao Y (2009). Analysis of the expression of Slit/Robo genes and the methylation status of their promoters in the hepatocellular carcinoma cell lines. Zhonghua Gan Zang Bing Za Zhi 17, 198-202.
20. Avci ME, Konu O, and Yagci T (2008). Quantification of SLIT-ROBO transcripts in hepatocellular carcinoma reveals two groups of genes with coordinate expression. BMC Cancer 8, 392.
21. Tanno T, Tanaka Y, Sugiura T, Akiyoshi H, Takenaka S, Kuwamura M, Yamate J, Ohashi F, Kubo K, and Tsuyama S (2006). Expression patterns of the slit subfamily mRNA in canine malignant mammary tumors. J Vet Med Sci 68, 1173-1177.
22. Wang B, Xiao Y, Ding BB, Zhang N, Yuan X, Gui L, Qian KX, Duan S, Chen Z, Rao Y, et al. (2003). Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 4, 19-29.
23. Yang XM, Han HX, Sui F, Dai YM, Chen M, and Geng JG (2010). Slit-Robo signaling mediates lymphangiogenesis and promotes tumor lymphatic metastasis. Biochem Biophys Res Commun 396, 571-577.
24. Latil A, Chene L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, and Cussenot O (2003). Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer 103, 306-315.
25. Yu J, Cao Q, Wu L, Dallol A, Li J, Chen G, Grasso C, Cao X, Lonigro RJ, Varambally S, et al. (2010). The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene 29, 5370-5380.
26. Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, Dobbin K, Melamed J, Kong X, Bosland M, et al. (2007). Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 38, 113-121.
27. Lloyd MC, Allam-Nandyala P, Purohit CN, Burke N, Coppola D, and Bui MM (2010). Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: how reliable is it? J Pathol Inform 1, 29.
28. Bolton KL, Garcia-Closas M, Pfeiffer RM, Duggan MA, Howat WJ, Hewitt SM, Yang XR, Cornelison R, Anzick SL, Meltzer P, et al. (2010). Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol Biomarkers Prev 19, 992-999.
29. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, and Ralhan R (2007). Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 80, 1873-1881.
30. Brantley-Sieders DM and Chen J (2004). Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 7, 17-28.
31. Pasquale EB (2010). Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10, 165-180.
32. Brantley-Sieders DM, Dunaway CM, Rao M, Short S, Hwang Y, Gao Y, Li D, Jiang A, Shyr Y, Wu JY, et al. (2011). Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Res 71, 976-987.
33. Kim HK, Zhang H, Li H, Wu TT, Swisher S, He D, Wu L, Xu J, Elmets CA, Athar M, et al. (2008). Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma. Neoplasia 10, 1411-1420.
34. Xu Y, Li WL, Fu L, Gu F, and Ma YJ (2010). Slit2/Robo1 signaling in glioma migration and invasion. Neurosci Bull 26, 474-478.
35. Werbowetski-Ogilvie TE, Seyed Sadr M, Jabado N, Angers-Loustau A, Agar NY, Wu J, Bjerkvig R, Antel JP, Faury D, Rao Y, et al. (2006). Inhibition of medulloblastoma cell invasion by Slit. Oncogene 25, 5103-5112.
36. Mertsch S, Schmitz N, Jeibmann A, Geng JG, Paulus W, and Senner V (2008). Slit2 involvement in glioma cell migration is mediated by Robo1 receptor. J Neurooncol 87, 1-7.
37. Carnero A, Blanco-Aparicio C, Renner O, Link W, and Leal JF (2008). The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8, 187-198.
38. Kramer SG, Kidd T, Simpson JH, and Goodman CS (2001). Switching repulsion to attraction: changing responses to slit during transition in mesoderm migration. Science 292, 737-740.
39. Song HJ, Ming GL, and Poo MM (1997). cAMP-induced switching in turning direction of nerve growth cones. Nature 388, 275-279.
40. Grone J, Doebler O, Loddenkemper C, Hotz B, Buhr HJ, and Bhargava S (2006). Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol Rep 15, 1437-1443.